Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Exp Pharmacol Physiol ; 35(1): 89-96, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18047634

RESUMEN

1. Human endothelial cells express proteinase-activated receptor-2 (PAR-2), inflammatory cytokines and trypsin (EC 3.4.21.4). However, little is known about the mechanism through which trypsin induces cytokine release from endothelial cells. 2. In the present study, we investigated the effect of trypsin on cytokine release from primary cultures of human umbilical vein endothelial cells (HUVEC) using an antibody based protein microarray and ELISA. 3. The results showed that 1 microg/mL trypsin induced release of 32 different inflammatory factors, whereas 100 micromol/L Ser-Leu-Ile-Gly-Lys-Val-NH2 (SLIGKV-NH2) only stimulated secretion of 16 inflammatory factors from HUVEC, as assessed by an antibody based protein microarray. Because the release of interleukin (IL)-1a, IL-8, IL-10 and IL-12 was markedly increased following PAR-2 activation, their release was investigated further using ELISA. Increases in release of up to approximately 4.8-, 4.3-, 4.1- and 1.8-fold were observed for IL-1a, IL-10, IL-12 and IL-8, respectively, when HUVEC were challenged with trypsin for 16 h. Agonist peptides of PAR-2, namely SLIGKV-NH2 and trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH2 (tc-LIGRLO-NH2), also provoked significant release of IL-8. Trypsin-induced cytokine release was inhibited by its inhibitors soybean trypsin inhibitor, alpha1-antitrypsin and the inhibitor peptide of PAR-2 Phe-Ser-Leu-Leu-Arg-Tyr-NH2 (FSLLRY-NH2). 4. These data indicate the action of trypsin on HUVEC is most likely through activation of PAR-2, suggesting that PAR-2-related mechanisms are involved in the inflammatory process in humans.


Asunto(s)
Citocinas/metabolismo , Células Endoteliales/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Oligopéptidos/farmacología , Receptor PAR-2/agonistas , Transducción de Señal/efectos de los fármacos , Tripsina/metabolismo , Venas Umbilicales/efectos de los fármacos , Antígenos CD/análisis , Células Cultivadas , Relación Dosis-Respuesta a Droga , Endoglina , Células Endoteliales/inmunología , Células Endoteliales/metabolismo , Ensayo de Inmunoadsorción Enzimática , Humanos , Interleucina-10/metabolismo , Interleucina-12/metabolismo , Interleucina-1alfa/metabolismo , Interleucina-8/metabolismo , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/análisis , Análisis por Matrices de Proteínas , Receptor PAR-2/metabolismo , Receptores de Superficie Celular/análisis , Tripsina/farmacología , Venas Umbilicales/citología , Venas Umbilicales/inmunología , Venas Umbilicales/metabolismo , alfa 1-Antitripsina/metabolismo
2.
Int J Biochem Cell Biol ; 38(4): 510-20, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16310401

RESUMEN

Poisonous snakebite wound is a popular disease worldwide. However, the pathogenesis remains unclear. In the present study, a novel metalloproteinase atrahagin in Chinese cobra (Naja atra) snake venom was purified, using heparin-sepharose followed by Superdex 75 gel filtration chromatography. Apart from its alpha-fibrinogenase activity, atrahagin potently activated human colon, lung and tonsil mast cells with the net histamine release being 25.9+/-4.4, 17.0+/-1.9, 13.2+/-3.6%, respectively. Time course studies revealed that the peak histamine release induced by atrahagin occurred at 12, 12 and 8 min following incubation of the enzyme with colon, lung and tonsil mast cells, respectively. The response of mast cells to atrahagin was abolished by preincubation of the cells with metabolic inhibitors or pertussis toxin, and by removal of Ca2+ and Mg2+ from the challenge buffer. In conclusion, activation of human mast cells by atrahagin indicated that the enzyme might contribute to the pathogenesis of snakebite wound.


Asunto(s)
Venenos Elapídicos/química , Liberación de Histamina/efectos de los fármacos , Mastocitos/metabolismo , Metaloproteasas/farmacología , Proteínas de Reptiles/farmacología , Animales , Células Cultivadas , Venenos Elapídicos/farmacología , Fibrinógeno/metabolismo , Humanos , Mastocitos/citología , Metaloproteasas/química , Metaloproteasas/aislamiento & purificación , Ratones , Ratones Endogámicos BALB C , Proteínas de Reptiles/química , Proteínas de Reptiles/aislamiento & purificación , Factores de Tiempo
3.
Acta Pharmacol Sin ; 25(12): 1677-84, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15569415

RESUMEN

AIM: To investigate the ability of proteinase inhibitors to modulate nucleated cell infiltration into the peritoneum of mice induced by tryptase and chymase. METHODS: Human lung tryptase and skin chymase were purified by a similar procedure involving high salt extraction, heparin agarose affinity chromatography followed by S-200 Sephacryl gel filtration chromatography. The actions of proteinase inhibitors on tryptase and chymase induced nucleated cell accumulation were examined with a mouse peritoneum model. RESULTS: A selective chymase inhibitor Z-Ile-Glu-Pro-Phe-CO2Me (ZIGPPF) was able to inhibit approximately 90 % neutrophil, 73 % eosinophil, 87 % lymphocyte and 60 % macrophage accumulation induced by chymase at 16 h following injection. Soy bean trypsin inhibitor (SBTI), chymostatin, and alpha1-antitrypsin showed slightly less potency than ZIGPPF in inhibition of the actions of chymase. While all tryptase inhibitors tested were able to inhibit neutrophil, eosinophil, and macrophage accumulation provoked by tryptase at 16 h following injection, only leupeptin, APC366, and aprotinin were capable of inhibiting tryptase induced lymphocyte accumulation. The inhibitors of tryptase tested were also able to inhibit tryptase induced neutrophil and eosinophil accumulation at 6 h following injection. When being injected alone, all inhibitors of chymase and tryptase at the concentrations tested by themselves had no significant effect on the accumulation of nucleated cells in the peritoneum of mice at both 6 h and 16 h. CONCLUSION: Proteinase inhibitors significantly inhibited tryptase and chymase-induced nucleated cell accumulation in vivo, and therefore they are likely to be developed as a novel class of anti-inflammatory drugs.


Asunto(s)
Peritoneo/citología , Inhibidores de Proteasas/farmacología , Serina Endopeptidasas/farmacología , Animales , Recuento de Células , Quimasas , Eosinófilos/citología , Eosinófilos/fisiología , Humanos , Linfocitos/citología , Linfocitos/fisiología , Macrófagos/citología , Macrófagos/fisiología , Masculino , Mastocitos/enzimología , Ratones , Ratones Endogámicos BALB C , Neutrófilos/citología , Neutrófilos/fisiología , Oligopéptidos/farmacología , Peritoneo/fisiología , Triptasas , alfa 1-Antitripsina/farmacología
4.
Acta Pharmacol Sin ; 24(9): 923-9, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12956943

RESUMEN

AIM: To investigate the actions of protease inhibitors on the enzymatic activities of tryptase and chymase in similar experimental systems. METHODS: Human lung tryptase and human skin chymase were purified by a similar procedure involving high salt extraction of tryptase, heparin agarose affinity chromatography, and S-200 Sephacryl gel filtration chromatography. Actions of protease inhibitors on tryptase and chymase activities were examined by enzyme assays. RESULTS: The specific activities of tryptase and chymase were 2.1 kU/g protein and 4.9 kU/g protein, respectively. Both preparations showed a single diffuse band on SDS-PAGE. Among non-native protease inhibitors, N-(1-hydroxy-2-naphthoyl)-L- arginyl-L-prolinamide hydrochloride (HNAP), leupeptin, antipain, benzamidine, and protamine inhibited more than 90 % enzymatic activity of tryptase, whereas soy bean trypsin inhibitor (SBTI), Z-Ile-Glu-Pro-Phe-CO2Me (ZIGPPM) and chymostatin inhibited more than 95 % enzymatic activity of chymase. Native protease inhibitors alpha 1-antitrypsin and secretory leukocyte protease inhibitor (SLPI) inhibited more than 90 % enzymatic activity of chymase, but lactoferrin appeared to enhance chymase enzymatic activity. All the 3 inhibitors had weak inhibitory actions on tryptase. CONCLUSION: The protease inhibitors tested had relatively good selectivity to either tryptase or chymase.


Asunto(s)
Mastocitos/efectos de los fármacos , Inhibidores de Proteasas/farmacología , Serina Endopeptidasas/metabolismo , Quimasas , Humanos , Leupeptinas/farmacología , Pulmón/citología , Pulmón/enzimología , Mastocitos/enzimología , Piel/citología , Piel/enzimología , Triptasas , alfa 1-Antitripsina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...